Retatrutide vs Survodutide

The retatrutide vs survodutide comparison is a triple-versus-dual receptor question, not a settled contest: retatrutide activates GLP-1, GIP, and glucagon receptors, while survodutide activates GLP-1 and glucagon. Both now have positive phase 3 obesity trials, both remain investigational in 2026, and no trial has compared them directly.

What is the core difference between retatrutide and survodutide?

Retatrutide adds a GIP signal to the two receptors that survodutide already shares: GLP-1 and glucagon. In plain English, both compounds turn down appetite through GLP-1 and add a glucagon pathway intended to increase energy use and address liver fat. Retatrutide adds a third metabolic signal through GIP, which also affects insulin response and appetite.

That makes this a clean triple vs dual agonist comparison on paper. The retatrutide profile covers the GLP-1/GIP/glucagon design; the survodutide profile explains why its GLP-1/glucagon pairing is being developed heavily for obesity and metabolic liver disease. More receptors do not automatically mean a better drug. Receptor balance, dose, tolerability, trial population, and the outcome being measured all matter.

Which produced more weight loss in trials?

Retatrutide produced the larger mean reduction in its own phase 3 obesity trial: 28.3% at 12 mg once weekly after 80 weeks in the efficacy estimand. Survodutide reached 13.0% with dose adjustment up to 6.0 mg once weekly after 76 weeks in the treatment-regimen estimand. Those figures answer what each trial observed; they do not prove retatrutide would beat survodutide in the same patients.

No direct head-to-head trial has compared them. The retatrutide vs survodutide weight loss numbers come from separate randomized, placebo-controlled studies with different protocols, participants, and estimands (retatrutide TRIUMPH-1; survodutide SYNCHRONIZE-1). Cross-trial comparisons are useful for spotting a signal, but they are a crooked ruler. Retatrutide gets the by-goal pick for following the largest phase 3 average, not a universal crown.

Which has the stronger liver-disease case?

Survodutide has the more direct liver-disease development case because a dedicated phase 2 randomized trial studied people with metabolic dysfunction-associated steatohepatitis, or MASH. More participants had MASH improvement without worsening fibrosis than with placebo, and phase 3 LIVERAGE testing is intended to confirm that finding (NCT04771273).

Retatrutide also has encouraging human liver data, but the cited evidence comes from a liver-fat sub-study within its phase 2 obesity program rather than a completed dedicated MASH trial. Retatrutide reported large liver-fat reductions at higher doses, and dedicated studies are moving the question forward. For someone tracking the more mature MASH-specific program, survodutide is the cleaner pick. For weight loss plus a liver-fat signal, both deserve attention within the broader GLP-1 and metabolic peptide landscape.

How mature is the evidence in 2026?

Retatrutide and survodutide both qualify for a Human RCT evidence tier because each now has randomized phase 3 human data for obesity. Retatrutide also has phase 3 data in type 2 diabetes, while survodutide has the dedicated phase 2 MASH result. Neither evidence badge means approved, fully characterized, or directly superior to the other.

Retatrutide has positive phase 3 results from TRIUMPH-1 in obesity and TRANSCEND-T2D-1 in diabetes, with additional trials underway. Survodutide has positive phase 3 obesity results from SYNCHRONIZE-1 and ongoing phase 3 liver-disease trials. Long-term safety and cardiovascular outcome questions are still being answered. Readers who want the grading rules behind that wording can see how peptide evidence is assessed.

What are the dose and safety differences?

Retatrutide and survodutide were both studied as once-weekly subcutaneous injections with gradual dose escalation, largely to reduce gastrointestinal side effects. The phase 3 obesity trials tested different molecules at different milligram ranges—up to 12 mg for retatrutide and 6.0 mg for survodutide—so the numbers cannot be converted into an equivalence or used as a personal protocol.

Both trials commonly reported nausea, vomiting, diarrhea, constipation, and reduced appetite. Retatrutide’s profile also notes a dose-dependent rise in heart rate. Survodutide’s long-term and cardiovascular safety picture is still being filled in. Trial dosing describes research, not instructions; the reconstitution calculator only performs vial arithmetic, and the half-life visualizer illustrates drug-level decline rather than deciding a schedule. Neither tool turns an investigational compound into an approved treatment.

Are retatrutide or survodutide FDA-approved?

Retatrutide and survodutide are both investigational and neither is FDA-approved for any use as of mid-2026. Neither is a dietary supplement. Legitimate access is through registered clinical trials, while products marketed online under either name are not FDA-approved products with verified identity, sterility, or dosing accuracy.

That shared status matters more than the receptor-count debate for anyone comparing practical availability. This is survodutide vs retatrutide as two clinical-stage programs, not two pharmacy options. Regulatory status can change after phase 3 readouts and filings, so the dated profiles and the site’s regulatory-status reference are the places to recheck. Today, the honest result is a set of by-goal research picks: retatrutide for the triple mechanism and larger separate-trial weight signal; survodutide for the dual mechanism and more direct MASH program. There is no universal winner.